



## **TO THE NATIONAL SECURITIES MARKET COMMISSION**

Madrid, 7 November 2024

In compliance with the duties of information provided for in article 227 of Law 6/2023 of 17 March on Securities Markets and Investment Services, Laboratorios Farmacéuticos ROVI, S.A. (hereinafter, "**ROVI**" or the "**Company**") hereby informs the National Securities Market Commission of the following

### **OTHER RELEVANT INFORMATION**

That the English version of the Communication of Inside Information (CIP) disseminated through the electronic means of the National Securities Market Commission (CNMV) on 7 November 2024 at 07:38 with registration number 2454, having noticed a material error which meant that the English version did not correspond to the Spanish version which is the one prevailing, has been replaced by the correct version which is the one recorded in the CNMV's records.

Yours faithfully,

Mr Juan López-Belmonte Encina  
Chairman and CEO  
Laboratorios Farmacéuticos ROVI, S.A.